AIRISE™ is an Innovative, Next Generation Immunotherapeutic.

(Nanoparticle-based Augmenting Immune Response and Inhibiting Suppressive Environment of tumors)

For the CO-DELIVERY of selected therapeutics (siRNA and adjuvant) to trigger anti-tumor immune response.

AIRISE™ utilizes a local treated tumor as a depot for neo-antigens in situ to trigger adaptive immunity (cytotoxic T cells) that kills tumors everywhere in the body.

AIRISE™ is an off-the-shelf drug with personalized effect without tedious neoantigen identification in conventional vaccines.

In-situ tumor vaccination triggers adaptive immune response.

AIRISE™ improves the effect of checkpoint inhibitors and raises survival rate.

Only 3 doses of AIRISE™ are effective in a bilateral melanoma mouse model.

Both tumors were substantially reduced; owing to CD8+ T cell response (confirmed by CD8 depletion).

Mice were cured and were tumor-free for > 17 months even after tumor rechallenge, indicating memory T cell effect.

Publication:

Ngamcherdtrakul, W., Reda, M., Nelson, M. A., Wang, R., Zaidan, H. Y., Bejan, D. S., Hoang, N. H., Lane, R. S., Luoh, S.-W., Leachman, S. A., Mills, G. B., Gray, J. W., Lund, A. W., Yantasee, W., In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. Adv. Mater. 2021, 2100628. https://doi.org/10.1002/adma.202100628